The COLOSSUS Project
Colorectal cancer is the third most common cancer in Europe. COLOSSUS is an EU-funded H2020 project that aims to provide new and more effective ways to classify patients with a specific type of colorectal cancer (microsatellite stable RAS mutant metastatic colorectal cancer or MSS RAS mt mCRC) and to develop better treatments for them. Our ultimate goal is to deliver a personalised medicine approach for patients with MSS RAS mt mCRC that is currently not available.
Project Partners
The COLOSSUS Project brings together a multidisciplinary team of 14 different partners from 8 different countries.
Latest News
Partner in the Spotlight: Halio Dx
This month we feature our partners at HalioDx. HalioDx (https://www.haliodx.com/) is the pioneer of immuno-oncology diagnostic, a transforming approach of cancer care that benefits from novel and deep understanding of the tumour immune microenvironment. The [...]
HalioDx Immunoscore® is independently reviewed in Molecular Diagnosis and Therapy
An independent review entitled “Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer” is published on March 30th, 2020 in Molecular Diagnosis and Therapy (Blair, H.A. Mol Diagn Ther (2020)[1] a specialized journal of Springer Nature [...]
COLOSSUS Partner in the Spotlight: Cancer Trials Ireland
Cancer Trials Ireland was established in 1996 under the name of Irish Cooperative Oncology Research Group (ICORG). A group of cancer consultants had the aim to create more opportunities for patients to access cutting edge [...]